Working… Menu

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03081858
Recruitment Status : Recruiting
First Posted : March 16, 2017
Last Update Posted : September 18, 2019
Lipac Oncology LLC
Information provided by (Responsible Party):
TesoRx Pharma, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2022